1. The National Comprehensive Cancer Network (NCCN). Breast guidelines, version 2.2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed March 17, 2022.
2. Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer [published correction appears in Ther Adv Med Oncol. 2018;10:1758835918810116];Thill;Ther Adv Med Oncol,2018
3. Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth;Hashizume;Neuro Oncol,2016
4. Inhibition of CDK4/CDK6 enhances radiosensitivity of HPV negative head and neck squamous cell carcinomas;Göttgens;Int J Radiat Oncol Biol Phys,2019
5. CDK4/6 inhibitor palbociclib amplifies the radiosensitivity to nasopharyngeal carcinoma cells via mediating apoptosis and suppressing DNA damage repair;Xie;Onco Targets Ther,2019